Purpose of Review
Therapeutic use, misuse, abuse, and diversion of controlled substances in managing chronic non-cancer pain remain a major concern for physicians, the government, payers, and patients. The challenge remains finding effective diagnostic tools that can be clinically validated to eliminate or substantially reduce the abuse of controlled prescription drugs, while still assuring the proper treatment of those patients in pain. Urine drug testing still remains an important means of adherence monitoring, but questions arise as to its relevance and effectiveness. This review examines the role of UDT, determines its utility in current clinical practice, and investigates its relevance in current chronic pain management.
A review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Literature was searched from year 2000 to present examining the relevance and role of UDT in monitoring chronic opioid therapy along with reliability and accuracy, appropriate use, overuse, misuse, and abuse. There are only a limited number of reviews and investigations on UDT, despite the fact that clinicians who prescribe controlled medications for chronic states commonly are expected to utilize UDT. Therefore, despite highly prevalent use, there is a limited publication base from which to draw in this present study.
Regardless of experience or training background, physicians and healthcare providers can much more adequately assess opioid therapy with the aid of UDT, which often requires confirmatory testing by a laboratory for clinical and therapeutic prescribing decisions. It has become a strongly recommended aspect of pain care with controlled substances locally, regionally, and nationally. Incorporating UDT for all patients in whom chronic opioid therapy is undertaken is consistent with state and national guidelines and best practice strategies. Practice standards vary as to the frequency of UDT locally, regionally, and nationally, however.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Available upon request from the corresponding author.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
• Volkow N. Prescription drug abuse—December 2011: a research update from the national institute on drugs abuse. Topics in Brief. 2011. This is a comprehensive research update from the National Institute on Drugs Abuse.
Administration SAaMHS. Drug Abuse Warning Network, 2010: area profiles of drug-related mortality HHA Publication No. (SMA) 12-4699, DAWN Series D-36. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2012.
Wunsch M, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict. 2009;18:5–14.
Standridge J, Adams S, Zotos A. Urine drug screening: a valuable office procedure. Am Fam Physician. 2010;81:635–40.
Peppin JF, Passik SD, Couto JE, Fine PG, Christo PJ, Argoff C, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012;13(7):886–96.
Rudd R, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52.
Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–30.
Gourlay D, Heit H, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107–12.
Dowell D, Haegerich T, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep. 2016;65:1–49.
Pesce A, West C, Egan City K, Strickland J. Interpretation of urine drug testing in pain patients. Pain Med. 2012;13:868–85.
Markway E, Baker S. A review of the methods, interpretation, and limitations of the urine drug screen. Orthopedics. 2011;34:877–81.
Knezevic N, Khan O, Beiranvand A, Candido K. Repeated quantitative urine toxicology analysis may improve chronic pain patient compliance with opioid therapy. Pain Physician. 2017;20:S135–S45.
Jannetto P, Bratanow N, Clark W, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline–using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2:489–526.
Manchikanti L, Malla Y, Wargo B, Fellows B. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients. Pain Physician. 2011;14:175–87.
Manchikanti L, Malla Y, Wargo B, Fellows B. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing. Pain Physician. 2011;14:259–70.
Kirsch K, Christo P, Heit H, Steffel K, Passik S. Specimen validity testing in urine drug monitoring of medications and illicit drugs: clinical implications. J Opioid Manag. 2015;11:53–9.
Lynch K. Specimen validity testing: is it “valid” for drug testing in pain management?, J Appl Lab Med. 2018;2:478–80.
•• Ali MM, Dowd WN, Classen T, Mutter R, Novak SP. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the National Survey of Drug Use and Health. Addict Behav. 2017;69:65–77 This paper discusses evidence from the National Survey of Druge Use and Health regarding prescription drug monitoring programs.
Bao Y, Pan Y, Taylor A, Radakrishnan S, Lu F, Pincus H, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016;35:1045–51.
Patrick S, Fry C, Jones T, Buntin M. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35:1324–32.
Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a tenyear perspective. Pain Physician. 2010;13:401–35.
Kosten T, George T. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1:13–20.
Passik S, Kirsch K. Opioid therapy in patients with a history of substance abuse. CNS Drug. 2004;18:13–25.
Passik S, Kirsch K. Assessing aberrant drug-taking behaviors in the patient with chronic pain. Curr Pain Headache Rep. 2004;8:289–94.
Kuehn B. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;297:249–51.
Victor GA, Walker R, Cole J, Logan TK. Opioid analgesics and heroin: examining drug misuse trends among a sample of drug treatment clients in Kentucky. Int J Drug Policy. 2017;46:1–6.
Ford JA, Sacra SA, Yohros A. Neighborhood characteristics and prescription drug misuse among adolescents: the importance of social disorganization and social capital. Int J Drug Policy. 2017;46:47–53.
Serdarevic M, Striley CW, Cottler LB. Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017;30:238–46.
Roxburgh A, Darke S, Salmon AM, Dobbins T, Jauncey M. Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney Medically Supervised Injecting Centre. Drug Alcohol Depend. 2017;176:126–32.
Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract. 2017;12:4.
Roy É, Arruda N, Leclerc P, Morissette C, Blanchette C, Blouin K, et al. Drug use practices among people who inject drugs in a context of drug market changes: challenges for optimal coverage of harm reduction programs. Int J Drug Policy. 2017;45:18–24.
Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abus Treat. 2017;78:1–7.
Estreet A, Archibalde P, Tirmazi MT, Goodman S, Cujoe T. Exploring social work student education: the effect of a harm reduction curriculum on student knowledge and attitudes regarding opioid use disorders. Subst Abus. 2017;52:00.
Syvertsen JL, Paquette CE, Pollini RA. Down in the valley: trajectories of injection initiation among young injectors in California’s Central Valley. Int J Drug Policy. 2017;44:41–9.
Meshesha LZ, Pickover AM, Teeters JB, Murphy JG. A longitudinal behavioral economic analysis of non-medical prescription opioid use among college students. Psychol Rec. 2017;67:241–51.
Bellew S, Barrett TW. Loperamide will stop you up but it can also bring you down. Ann Emerg Med. 2017;69:786–91.
Compton W, Jones C, Baldwin G. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–63.
Manchikanti L, Kaye A, Knezevic N, McAnally H, Slavin K, Trescot A, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017;20:S30S92.
Gourlay D, Heit H. Pain and addiction: managing risk through comprehensive care. J Addict Dis. 27:23–30.
Manchikanti L, Malla Y, Wargo B, Cash K, Pampati V, Damron K, et al. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Pain Physician. 2010;13:E1–E22.
•• Knezevic N, Khan O, Beiranvand A, Candido K. Repeated quantitative urine toxicology analysis may improve chronic pain patient compliance with opioid Therapy. Pain Physician. 2017;20:S135–S45 This analysis suggests that repeated quantitative urine toxicology analysis may improve compliance in patients using chronic opioids.
Yee YD, Hughes M, Guo A, Barakat N, Tse S, Ma J, et al. Observation of improved adherence with frequent urine drug testing in patients with pain. J Opioid Manag. 2014;10:111–8.
Morasco B, Krebs E, Cavanagh R, Hyde S, Crain A, Dobscha S. Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy. J Opioid Manag. 2015;11:45–51.
Christo P, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki D, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14:123–43.
Butler S, Fernandez K, Benoit C, Budman S, Jamison R. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9:360–72.
Butler S, Budman S, Fernandez K, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130:144–56.
Moore T, Jones T, Browder J, Daffron S, Passik S. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009;10:1426–33.
Hamill-Ruth R, Larriviere K, McMasters M. Addition of objective data to identify risk for medication misuse and abuse: the inconsistency score. Pain Med. 2013;14:1900–7.
• Ko M, Woster P, Smith T. (205) Predictors of illicit substance use assessed by urine drug monitoring in patients prescribed opioid medications. The Journal of Pain (2016);17(4):S27. https://doi.org/10.1016/j.jpain.2016.01.108. This review is an excellent manuscript on profiles of drug-related mortality.
Woster P, Ko M, Smith T. Predictors of medication adherence assessed by urine drug monitoring in patients prescribed opioid medications: relationship with opioid dose. J Pain. 2016;17:S27.
Morasco B, Peters D, Krebs E, Kovas A, Hart K, Dobscha S. Predictors of urine drug testing for patients with chronic pain: results from a national cohort of U.S. veterans. Subst Abus. 37:82–7.
Manchikanti R, Manchikanti L, Damron K, Brandon D, McManus C, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9:57–60.
Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2–guidance. Pain Physician. 2012;15:S67–S116.
Nafzinger A, Bertino J. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009;25:73–9.
Reisfield G, Bertholf R, Barking R, Webb F, Wilson G. Urine drug test interpretation: what do physicians know? J Opioid Manag. 2007;3:80–6.
Reisfield G, Graham N, Gold M. Urine drug testing is still an invaluable resource for primary care. Ann Intern Med. 2010;153:420 author reply -1.
Moeller K, Lee K, Kissack J. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83:66–76.
Reisfield G, Salazar E, Bertholf R. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37:301–14.
Wu AH. Integrity of urine specimens submitted for toxicologic analysis: adulteration, mechanisms of action, and laboratory detection. Forensic Sci Rev. 1998;10:47–65.
Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276(5321):2048–50.
Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci. 2001;21(3):823–33.
Savage SR, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, et al. Cannabis in pain treatment: clinical and research considerations. J Pain. 2016;17(6):654–68.
Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manag. 2004;27(3):260–7.
Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Damron KS, et al. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Pain Physician. 2010;13(1):E1–e22.
St John A, Price CP. Existing and emerging technologies for point-of-care testing. Clin Biochem Rev. 2014;35(3):155–67.
Raouf M, Bettinger JJ, Fudin J. A practical guide to urine drug monitoring. Fed Pract. 2018;35(4):38–44.
James HN. Risk management for point-of-care testing. Ejifcc. 2014;25(2):154–61.
Drummer OH. Drug testing in oral fluid. Clin Biochem Rev. 2006;27(3):147–59.
Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem. 2009;55(11):1910–31.
Dams R, Choo RE, Lambert WE, Jones H, Huestis MA. Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. Drug Alcohol Depend. 2007;87(2–3):258–67.
Cone EJ. New developments in biological measures of drug prevalence. In: Harrison L, Hughes A, editors. Validity self-reported drug use Improv Accuracy Surv Estim. Bethesda: National Institute on Drug Abuse; 1997.
Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26(2):200–5.
Crouch DJ. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int. 2005;150(2–3):165–73.
Lotsch J, von Hentig N, Freynhagen R. Cross sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009;19:429–36.
Barakat N, Atayee R, Best B. Relationship between the concentration of hydrocodone and its converstion to hydromorphone in chronic pain patients using urinary excretion data. J Anal Toxicol. 2012;36:257–64.
Conflict of Interest
The authors declare no conflict of interest as relates to this body of work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Alternative Treatments for Pain Medicine
About this article
Cite this article
Chakravarthy, K., Goel, A., Jeha, G.M. et al. Review of the Current State of Urine Drug Testing in Chronic Pain: Still Effective as a Clinical Tool and Curbing Abuse, or an Arcane Test?. Curr Pain Headache Rep 25, 12 (2021). https://doi.org/10.1007/s11916-020-00918-z
- Controlled substances
- Illicit drugs
- Substance use disorder
- Prescription drug monitoring programs
- Adherence monitoring
- Compliance monitoring
- Urine drug testing
- False positives
- False negatives